Weigh Pros and Cons of Palforzia for Peanut Allergy

October 2020

You’ll hear about Palforzia, the first FDA-approved option for peanut allergy desensitization.

It doesn’t allow patients to freely eat peanut products. But it may minimize an allergic reaction from accidental exposure.

Palforzia is a peanut allergen powder given orally in increasing doses to patients 4 to 17 years old. It’s an alternative to peanut oral immunotherapy already being done by some specialists.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Clarify Which Patients Need a COVID-19 Viral Test
Influenza Compare Oseltamivir and Baloxavir for Treating or Preventing Flu
Supplements Know Which Supplements Promoted for COVID-19 May Be Risky
Stroke Don’t Jump to Ticagrelor Plus Aspirin After Stroke
Immunizations Answer Questions About Vaccinations During COVID-19
Allergic Reactions Weigh Pros and Cons of Palforzia for Peanut Allergy
Osteoporosis Know How Meds for Postmenopausal Osteoporosis Stack Up
Substance Use Disorder Address Barriers to Treating Opioid Use Disorder During COVID-19
Med Safety Put Skin Cancer Risk With Hydrochlorothiazide in Perspective
Infectious Diseases Clarify Remdesivir and Convalescent Plasma Use for COVID-19
Acute Care Know When to Add ECG Monitoring With Droperidol

Weigh Pros and Cons of Palforzia for Peanut Allergy

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents